Thad Wolfram serves on the Board of Directors of Prolerity Clinical Research. With more than 20 years of experience across clinical trials, health systems, and the pharmaceutical industry, Thad brings deep operating experience in clinical research site networks and a track record of building businesses that expand patient access to research.

Thad is Chief Executive Officer of Longitude Clinical Trial Services, a Longitude Health utility formed in 2026 to broaden health system participation in clinical research through shared infrastructure, operational support, and access to representative patient populations.

Previously, Thad served as President of EmVenio Research, where he led the company’s growth in community research sites that bring trials directly to underserved populations, and following EmVenio’s acquisition by Professional Case Management, as Chief Strategy Officer of PCM. Earlier, he was President of Matrix Clinical Trials and Executive Director of Corporate Strategy at PPD. He began his career as a laboratory scientist at Pfizer before moving into life sciences strategy consulting at PA Consulting and EY.

He holds an MBA from Rensselaer Polytechnic Institute – The Lally School of Management, an MS from Michigan State University in Industrial Microbiology / Medical Microbiology, and a BS in Microbiology and Molecular Genetics from Michigan State University.